scholarly journals 748P Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)

2021 ◽  
Vol 32 ◽  
pp. S742-S743
Author(s):  
M. Romeo Marin ◽  
M. Gil-Martin ◽  
L. Gaba Garcia ◽  
C. Fina ◽  
Á. Taus ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Parp Inhibitors ◽  
High Grade ◽  
Real World Data ◽  
World Data ◽  
Endometrioid Ovarian Cancer

scholarly journals 824P Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p)

2020 ◽  
Vol 31 ◽  
pp. S622
Author(s):  
A. Plaja Salarich ◽  
I. Teruel García ◽  
B. Pardo Burdalo ◽  
M. Gil-Martin ◽  
J.M. Piulats ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Parp Inhibitors ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Real World Data ◽  
World Data

scholarly journals 281 Real-world-data on platinum outcomes after parp inhibitors progression in high grade serous ovarian cancer patients

2020 ◽  
Author(s):  
Andrea Plaja Salarich ◽  
Iris Teruel García ◽  
Beatriz Pardo Burdalo ◽  
Marta Gil-Martin ◽  
Josep Maria Piulats Rodriguez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Parp Inhibitors ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Real World Data ◽  
World Data

scholarly journals 123 Real world data of treatment and outcome of patients with high grade AOC (advanced ovarian cancer) in Germany (QS Ovar)

2021 ◽  
Author(s):  
P Harter ◽  
A Du Bois ◽  
F Hilpert ◽  
M Kerkmann ◽  
J Sehouli ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Advanced Ovarian Cancer ◽  
High Grade ◽  
Real World Data ◽  
World Data

scholarly journals 510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial

2020 ◽  
Author(s):  
Douglas Cartwright ◽  
Patricia Roxburgh ◽  
Barbara Stanley ◽  
Jennifer Brown ◽  
Alistair Mclaren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Recurrent Ovarian Cancer ◽  
Wild Type ◽  
Real World Data ◽  
World Data ◽  
Platinum Sensitive

scholarly journals Brain metastases in primary ovarian cancer: Real-world data

2018 ◽  
Vol 29 ◽  
pp. viii338 ◽  
Author(s):  
E. Ratner ◽  
M. Bala ◽  
M. Louie-Gao ◽  
S. Hazard ◽  
P. Brastianos
Keyword(s):  
Ovarian Cancer ◽  
Brain Metastases ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
Primary Ovarian Cancer

scholarly journals Real-world effectiveness of Human Papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers

2020 ◽  
Author(s):  
Christian Dehlendorff ◽  
Louise Baandrup ◽  
Susanne K Kjaer
Keyword(s):  
Human Papillomavirus ◽  
Real World ◽  
Cumulative Incidence ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Hazard Rates ◽  
High Grade ◽  
Real World Data ◽  
Human Papillomavirus Vaccination ◽  
World Data

Abstract Background Vaccination against human papillomavirus (HPV) has proven to be effective against severe cervical lesions and genital warts, whereas no previous study has provided real-world data on the HPV vaccine effectiveness against high-grade vulvovaginal lesions. Methods A cohort of all women aged 17–26 years, living in Denmark during 2006–2019 was followed in nationwide registers for individual-level information about HPV vaccination and first diagnoses of vulvar and vaginal high-grade intraepithelial lesions or worse (HSIL+). The cumulative incidence of vulvar and vaginal HSIL+, respectively, was estimated with the Aalen-Johansen estimator and Cox proportional hazards regression was used to estimate hazard ratios (HRs) for vulvar and vaginal lesions separately comparing women vaccinated at age <16 years and at age 17–26 years with unvaccinated women. Results The cohort consisted of 514,537 women, of which 50.6% were vaccinated at baseline (<16 years), 31.8% were vaccinated during follow-up (17–26 years) and 17.6% remained unvaccinated. The cumulative incidence was less than 0.6‰ for vulvar HSIL+ and less than 0.2‰ for vaginal HSIL+. Adjusted analyses showed reduced hazard rates for both vulvar (HR = 0.22, 95% CI = 0.13 to 0.38) and vaginal HSIL + (HR = 0.16, 95% CI = 0.04 to 0.55) for women vaccinated at age ≤16 years compared to unvaccinated women. For women vaccinated at 17–26 years, the reductions in hazard rates were smaller for vaginal HSIL+ and close to zero for vulvar HSIL+. Conclusion HPV vaccination before 17 years of age reduces the risk of vulvar and vaginal HSIL+ based on real-world data.

Use of alkylating chemotherapy in high-grade neuroendocrine tumours: Evaluation of real-world data.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 78-78
Author(s):  
Arani Sathiyapalan ◽  
Michael Susmoy Sanatani ◽  
Stephen Welch ◽  
Walter Ilarion Kocha ◽  
Sue Richter
Keyword(s):  
Real World ◽  
Neuroendocrine Tumours ◽  
Alkylating Agents ◽  
Treatment Decision ◽  
Treatment Discontinuation ◽  
High Grade ◽  
Real World Data ◽  
World Data ◽  
Current Series ◽  
Significant Difference

78 Background: High-grade neuroendocrine tumours (NETs) are believed to have activity to certain alkylating agents, although data are scant. These regimens include streptozotocin (STZ) (used in combination with doxorubicin or 5-fluorouracil) and dacarbazine (DTIC). Current series report variable responses between 6 – 69%. Our objective was to evaluate our real world data to better understand treatment decision-making and clinical outcomes with alkylating agents in advanced high-grade NETs. Methods: We reviewed the medical records of 36 patients with metastatic NETs who received alkylating systemic chemotherapy with either a DTIC regimen (n = 15) or STZ based regimen (n = 21). Patient cases were evaluated for age, time to treatment failure (TTF), time to progression (TTP Results: Among 36 patients treated, the predominant primary NET was pancreas (n = 28) with a median age at treatment of 61.9 years. Observed TTF was similar with both regimens (STZ: 3 months and DTIC: 4 months), however there was prolonged TTP of 11 months with STZ vs. 5.3 months with DTIC (p = 0.047). There was no significant difference in OS with a mean of 48.7 months (DTIC) vs. 47.6 months (STZ) (p = 0.47). Baseline progression at treatment initiation was higher in DTIC at 77% versus 57% in STZ. The predominant cause of treatment discontinuation in both groups was progressive disease; DTIC (71%) versus STZ (42%). Toxicity resulted in treatment discontinuation in 19% for STZ vs 7% for DTIC. Other causes of treatment cessation were completion of the intended treatment. Conclusions: In the groups evaluated, STZ containing regimens demonstrated prolonged PFS in comparison to DTIC, but there was no difference in OS between the two groups. Additionally, despite STZ appearing to have an increased toxicity rate, the rate of cessation between the groups was similar. This real world evaluation suggests similar efficacy with improved tolerability of DTIC based chemotherapy as a potential alternative to other alkylating agents.

scholarly journals Olaparib treatment in older patients with ovarian cancer: need for ‘real-world’ data beyond clinical trials

2020 ◽  
Vol 14 ◽  
Author(s):  
Gabor Liposits ◽  
Christian Nielsen Wulff ◽  
Anne Otland ◽  
Lars Ulrik Fokdal
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Real World ◽  
Older Patients ◽  
Real World Data ◽  
World Data

NIRAPARIB OUTCOMES IN BRCA WILD-TYPE PLATINUM SENSITIVE RECURRENT OVARIAN CANCER: A COMPARISON OF REAL-WORLD DATA TO THE NOVA TRIAL.

2020 ◽  
Author(s):  
Douglas Cartwright ◽  
Patricia Roxburgh ◽  
Barbara Stanley ◽  
Jennifer Brown ◽  
Alistain McClaren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Recurrent Ovarian Cancer ◽  
Wild Type ◽  
Real World Data ◽  
World Data ◽  
Platinum Sensitive
Sign in / Sign up

Export Citation Format

Share Document